Paolo Strati, M.D.

Peer-Reviewed Articles

1. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
2. Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol 98(7):1611-1616, 2019. e-Pub 2019. PMID: 31093708.
3. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE, Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 94(6):E150-E153, 2019. e-Pub 2019. PMID: 30785215.
4. Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L. Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. Cancers (Basel) 11(7), 2019. e-Pub 2019. PMID: 31248056.
5. Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood 133(26):2800-2802, 2019. e-Pub 2019. PMID: 31101626.
6. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. PMID: 31076409.
7. Strati P, Neelapu SS. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Curr Oncol Rep 21(5):38, 2019. e-Pub 2019. PMID: 30919158.
8. Strati P, Gabutti C, Thompson PA, Kontoyiannis DP, Ferrajoli A. Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. Leuk Lymphoma 60(2):535-537, 2019. e-Pub 2018. PMID: 29911929.
9. Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma 60(2):507-510, 2019. e-Pub 2018. PMID: 29966471.
10. Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica 104(2):e65-e67, 2019. e-Pub 2018. PMID: 30190343.
11. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
12. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
13. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103(9):e416-e418, 2018. e-Pub 2018. PMID: 29622656.
14. Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma 59(7):1672-1676, 2018. e-Pub 2017. PMID: 29119847.
15. Autore F, Strati P, Laurenti L, Ferrajoli A. Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. Haematologica 103(6):931-938, 2018. e-Pub 2018. PMID: 29748447.
16. Strati P, Jain N, O'Brien S. Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc 93(5):651-664, 2018. PMID: 29728204.
17. Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI. Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book 38:592-603, 2018. PMID: 30231316.
18. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
19. Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109-121, 2018. e-Pub 2017. PMID: 29143068.
20. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk 18(1):e103-e108, 2018. e-Pub 2017. PMID: 29196178.
21. Akcan T, Strati P, Yan M, Idowu M. A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge. Case Rep Hematol 2018:9079462, 2018. e-Pub 2018. PMID: 30647982.
22. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica 102(12):e494-e496, 2017. e-Pub 2017. PMID: 28798068.
23. Strati P, Benton CB, Manshouri T, Zhang Y, Bove JE, Sanchez-Petitto G, Verstovsek S. JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. Leuk Res 63:53-55, 2017. e-Pub 2017. PMID: 29101828.
24. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, Estrov Z, Kadia T, O'Brien S, Dabaja B, Bueso-Ramos C, Strati P, Bivins C, Pierce S, Kantarjian H. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol 92(9):924-928, 2017. e-Pub 2017. PMID: 28556489.
25. Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, Cerhan JR, Slager SL, Shanafelt TD. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 178(3):394-402, 2017. e-Pub 2017. PMID: 28580636.
26. Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE, Shanafelt TD. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol 178(1):99-105, 2017. e-Pub 2017. PMID: 28386906.
27. Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
28. Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol 96(5):733-738, 2017. e-Pub 2017. PMID: 28247057.
29. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
30. Ho TP, Strati P, Chon TY. 65-Year-Old Man With Weight Loss and Progressive Acral Necrosis. Mayo Clin Proc 92(4):605-608, 2017. e-Pub 2017. PMID: 28238397.
31. Strati P. Treatment for relapsed or refractory chronic lymphocytic leukaemia: an ongoing challenge. Lancet Haematol 4(3):e97-e98, 2017. PMID: 28257754.
32. Strati P, Chaffee KG, Achenbach SJ, Slager SL, Leung N, Call TG, Ding W, Parikh SA, Kay NE, Shanafelt TD. Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. Haematologica 102(1):e22-e25, 2017. e-Pub 2016. PMID: 27634202.
33. Kay NE, Strati P, LaPlant BR, Leis JF, Nikcevich D, Call TG, Pettinger AM, Lesnick CE, Hanson CA, Shanafelt TD. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. Oncotarget 7(48):78269-78280, 2016. PMID: 27861157.
34. Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol 3(9):e407-14, 2016. e-Pub 2016. PMID: 27570087.
35. Strati P, Gharaibeh KA, Leung N, Cosio FG, Call TG, Shanafelt TD. Solid organ transplant in individuals with monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. Br J Haematol 174(1):162-5, 2016. e-Pub 2015. PMID: 26436615.
36. Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, Chaffee KG, Call TG, Shanafelt TD. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica 101(4):458-65, 2016. e-Pub 2016. PMID: 26819053.
37. Parikh SA, Strati P, Tsang M, West CP, Shanafelt TD. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood 127(14):1752-60, 2016. e-Pub 2016. PMID: 26841802.
38. Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica 100(9):1180-8, 2015. e-Pub 2015. PMID: 26088927.
39. Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ. Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 15(7):420-7, 2015. e-Pub 2015. PMID: 25800543.
40. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood 126(4):454-62, 2015. e-Pub 2015. PMID: 26065657.
41. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma 56(6):1878-80, 2015. e-Pub 2014. PMID: 25311497.
42. Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90(4):276-81, 2015. e-Pub 2015. PMID: 25530214.
43. Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer 121(6):876-82, 2015. e-Pub 2014. PMID: 25410759.
44. Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res 38(10):1212-6, 2014. e-Pub 2014. PMID: 25217891.
45. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
46. Strati P, Manning JT, Ok CY, Garcia-Manero G, Estrov Z. Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leuk Lymphoma 55(6):1425-7, 2014. e-Pub 2014. PMID: 23987820.
47. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
48. Strati P, Ferrajoli A, Lerner S, O'Brien S, Wierda W, Keating MJ, Faderl S. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55(4):828-33, 2014. e-Pub 2013. PMID: 23808813.
49. Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120(3):373-80, 2014. e-Pub 2013. PMID: 24151050.
50. Strati P, O'Brien S. Reply to myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 120(3):452, 2014. e-Pub 2013. PMID: 24151154.
51. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 2013. e-Pub 2013. PMID: 23943357.
52. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11; quiz 2920, 2013. e-Pub 2013. PMID: 23896412.
53. Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 2013. e-Pub 2013. PMID: 23969309.
54. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122(5):734-7, 2013. e-Pub 2013. PMID: 23801633.
55. Greaves WO, Verma S, Bisrat T, Strati P, Rahimi H, Paladugu AV, Luthra R, Patel KP, Medeiros LJ, Yao H, Pierce S, Bueso-Ramos CE, Verstovsek S. TP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma 54(7):1552, 2013. e-Pub 2012. PMID: 23121011.
56. Strati P, Cortes J, Faderl S, Kantarjian H, Verstovsek S. Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk 13(3):287-91, 2013. e-Pub 2012. PMID: 23123105.
57. Daver N, Strati P, Jabbour E, Kadia T, Luthra R, Wang S, Patel K, Ravandi F, Cortes J, Qin Dong X, Kantarjian H, Garcia-Manero G. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 88(1):56-9, 2013. e-Pub 2012. PMID: 23115106.
58. Strati P, Caligaris-Cappio F. A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?. Curr Opin Oncol 23(5):455-60, 2011. PMID: 21681094.
59. Camaschella C, Strati P. Recent advances in iron metabolism and related disorders. Intern Emerg Med 5(5):393-400, 2010. e-Pub 2010. PMID: 20424932.
60. Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. Haematologica. e-Pub 2019. PMID: 31073068.
61. Strati P, Ferrajoli A. Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach. Drugs Aging. e-Pub 2019. PMID: 31055788.